MethylAge Epigenetic Biological Age Test

The MethylAge epigenetic test at 5P Medicine measures two key DNA methylation markers — 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) — to determine how fast a patient's cells are actually ageing compared to their chronological age. High 5hmC is associated with active, 'younger' DNA; a low ratio suggests accelerated epigenetic ageing. Results translate directly into a biological age assessment, with personalised lifestyle recommendations designed to slow or reverse measurable epigenetic ageing. This test is particularly valuable for patients aged 35+ who want objective data on their cellular ageing trajectory before symptoms appear.

Epigenetics describes how external factors — diet, stress, sleep, environmental toxins, exercise — alter which genes are expressed without changing the underlying DNA sequence. DNA methylation is one of the best-studied epigenetic mechanisms: the addition or removal of methyl groups to cytosine bases acts as an on/off switch for gene expression, and the overall pattern shifts in characteristic ways as we age. The MethylAge test used at 5P Medicine quantifies two specific methylation states in a blood sample: 5-methylcytosine (5mC) reflects baseline DNA methylation levels and correlates with gene silencing and genomic stability. Global hypomethylation — a reduction in 5mC across the genome — is a well-documented hallmark of cellular ageing and is associated with increased cancer risk and loss of transcriptional regulation. 5-hydroxymethylcytosine (5hmC) is an oxidised form of 5mC generated by TET enzyme activity. High 5hmC concentrations are found in active, transcriptionally 'young' chromatin. The 5hmC:5mC ratio therefore serves as a proxy for the dynamism and youthfulness of a cell's epigenome. By comparing a patient's methylation profile to age-matched reference populations, the test yields a biological age estimate that may be significantly younger or older than chronological age, depending on lifestyle history. The discrepancy — sometimes called 'epigenetic age acceleration' — is a strong predictor of longevity-related outcomes in published research. MUDr. Hora reviews results in the context of the patient's genomic data, hormone profile, microbiome findings and lifestyle history. The personalised recommendations that follow may include targeted nutritional interventions (methyl donors such as folate, B12, choline), stress-reduction protocols, sleep optimisation, adjusted physical activity and specific nutraceuticals shown to favourably modulate methylation patterns. The test is most valuable when repeated at six to twelve month intervals to assess whether lifestyle interventions are producing measurable epigenetic improvements. Within 5P Medicine's AI programmes, it serves as a key endpoint for tracking the success of multi-domain health interventions.